Handelsbanken Fonder AB Has $9.10 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Handelsbanken Fonder AB increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 930.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 246,069 shares of the biopharmaceutical company's stock after purchasing an additional 222,200 shares during the quarter. Handelsbanken Fonder AB owned 0.19% of Halozyme Therapeutics worth $9,095,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HALO. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in Halozyme Therapeutics in the 4th quarter valued at about $196,000. EP Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics during the third quarter worth approximately $211,000. Pathstone Family Office LLC acquired a new stake in Halozyme Therapeutics during the third quarter worth approximately $219,000. Tocqueville Asset Management L.P. acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at $225,000. Finally, Gallacher Capital Management LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at $235,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the sale, the senior vice president now owns 156,558 shares of the company's stock, valued at approximately $6,519,075.12. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 30,000 shares of company stock valued at $1,196,800 over the last 90 days. 2.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Benchmark restated a "buy" rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, April 17th. TD Cowen started coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They set an "outperform" rating and a $54.00 price objective for the company. TheStreet cut Halozyme Therapeutics from a "b-" rating to a "c+" rating in a report on Monday, January 22nd. Finally, StockNews.com upgraded Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research note on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $53.29.

Halozyme Therapeutics Stock Down 1.7 %

Shares of HALO stock traded down $0.66 on Thursday, hitting $38.46. The stock had a trading volume of 693,348 shares, compared to its average volume of 1,237,922. Halozyme Therapeutics, Inc. has a 52-week low of $29.85 and a 52-week high of $45.00. The firm has a market capitalization of $4.89 billion, a price-to-earnings ratio of 18.23, a P/E/G ratio of 0.45 and a beta of 1.25. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The stock's 50 day moving average is $39.79 and its 200-day moving average is $37.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The company had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 3.45 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.